Liver Cirrhosis Patients Homozygous for MTHFR C677T Develop Portal Vein Thrombosis 8 Years Earlier Than Wild Type
暂无分享,去创建一个
[1] C. Samama,et al. A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing , 2022, Research and practice in thrombosis and haemostasis.
[2] Ge Guan,et al. A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis , 2022, Annals of medicine.
[3] Sophia Seen. Chronic liver disease and oxidative stress – a narrative review , 2021, Expert review of gastroenterology & hepatology.
[4] M. Margaglione,et al. Homozygous methylentetrahydrofolate reductase C667T genotype anticipates age at venous thromboembolism by one decade , 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[5] D. Valla,et al. Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study , 2020, European journal of gastroenterology & hepatology.
[6] S. Resino,et al. MTHFR rs1801133 Polymorphism Is Associated With Liver Fibrosis Progression in Chronic Hepatitis C: A Retrospective Study , 2020, Frontiers in Medicine.
[7] Jiahuai Han,et al. Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure. , 2019, Immunity.
[8] Z. Kadry,et al. Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[9] Z. Kadry,et al. Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta‐analysis , 2019, Research and practice in thrombosis and haemostasis.
[10] Yinan Wei,et al. Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis. , 2019, Immunity.
[11] B. Zarić,et al. Homocysteine and Hyperhomocysteinaemia. , 2019, Current medicinal chemistry.
[12] G. Corazza,et al. Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis , 2019, Hepatology communications.
[13] Zhaoxi Sun,et al. Thermodynamics of helix formation in small peptides of varying length in vacuo, in implicit solvent, and in explicit solvent , 2018, Journal of Molecular Modeling.
[14] Qinghua Zeng,et al. Correlations between methylenetetrahydrofolate reductase gene polymorphisms and venous thromboembolism: A meta-analysis of 99 genetic association studies , 2018, European journal of preventive cardiology.
[15] S. Sarin,et al. Decreased protein C function predicts mortality in patients with cirrhosis , 2018, International journal of laboratory hematology.
[16] Wei Chen,et al. An evidence-based approach to globally assess the covariate-dependent effect of the MTHFR single nucleotide polymorphism rs1801133 on blood homocysteine: a systematic review and meta-analysis. , 2018, The American journal of clinical nutrition.
[17] J. Qian,et al. Allosteric control of human cystathionine β-synthase activity by a redox active disulfide bond , 2018, The Journal of Biological Chemistry.
[18] Huirong Liu,et al. Nitration‐mediated deficiency of cystathionine &bgr;‐synthase activity accelerates the progression of hyperhomocysteinemia , 2017, Free radical biology & medicine.
[19] D. Christodoulou,et al. Haemostatic balance in patients with end-stage cirrhosis: low protein C is the predominant coagulant protein deficiency. , 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[20] G. Carvalhal,et al. Glutamine prevents oxidative stress in a model of portal hypertension , 2017, World journal of gastroenterology.
[21] Georg Heinze,et al. Five myths about variable selection , 2017, Transplant international : official journal of the European Society for Organ Transplantation.
[22] F. Gentile,et al. Nitric oxide metabolites, nitrative stress, and paraoxonase activity in hepatopulmonary syndrome , 2016, Scandinavian journal of gastroenterology.
[23] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[24] D. Fan,et al. Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd–Chiari syndrome and portal vein thrombosis: A systematic review and meta‐analysis of observational studies , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.
[25] H. Blom,et al. Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular one-carbon metabolism , 2013, Clinical chemistry and laboratory medicine.
[26] C. Curry,et al. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing , 2013, Genetics in Medicine.
[27] S. Bessa,et al. Portal vein thrombosis in Egyptian patients with liver cirrhosis: Role of methylenetetrahydrofolate reductase C677T gene mutation , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[28] Ning Yang,et al. Protein C and D‐dimer are related to portal vein thrombosis in patients with liver cirrhosis , 2010, Journal of gastroenterology and hepatology.
[29] E. Lonn,et al. Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism , 2007, Annals of Internal Medicine.
[30] M. Margaglione,et al. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation , 2006, Thrombosis and Haemostasis.
[31] S. Tyagi,et al. Mechanisms of homocysteine-induced oxidative stress. , 2005, American journal of physiology. Heart and circulatory physiology.
[32] A. Cimmino,et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients , 2005, Hepatology.
[33] H. Blom,et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. , 2004, Blood.
[34] T. Orfeo,et al. Homocysteine Inhibits Inactivation of Factor Va by Activated Protein C* , 2001, The Journal of Biological Chemistry.
[35] S. Olliff,et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. , 2000, Transplantation.
[36] J. Morrow,et al. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[37] P. Mannucci,et al. Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: relationships with plasma homocysteine levels. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[38] J. Sadler,et al. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. , 1991, The Journal of clinical investigation.
[39] C. Schöneich. Sulfur Radical-Induced Redox Modifications in Proteins: Analysis and Mechanistic Aspects. , 2017, Antioxidants & redox signaling.
[40] C. Byrne,et al. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. , 1998, Blood.
[41] M. Margaglione,et al. Thrombophilic Genotypes in Subjects with Idiopathic Antiphospholipid Antibodies – Prevalence and Significance , 1998, Thrombosis and Haemostasis.